Literature DB >> 2584609

Pilot scale production of a human monoclonal antibody against human immunodeficiency virus HIV-1.

A Jungbauer1, C Tauer, E Wenisch, F Steindl, M Purtscher, M Reiter, F Unterluggauer, A Buchacher, K Uhl, H Katinger.   

Abstract

Human monoclonal antibodies against the transmembrane protein gp41 of HIV-1 were isolated and purified on a pilot scale. A purification scheme was established for the production of human monoclonal antibodies on the gram scale. 50 1 of culture supernatant can be treated in one purification cycle. The hybridomas were mass cultured in an airlift fermenter. The culture broth was clarified by microfiltration and chromatographed on CM-Sepharose fast flow and protein A Superose. Scale up of the high performance affinity chromatography from 1 ml protein A Superose up to 40 ml is described. All desalting steps were performed by gel filtration on Sephadex G-25 coarse. The yield of the whole purification procedure is in the range of 50-60%. The purity is higher than 99.9%. DNA and reverse transcriptase could not be detected. The whole method is designed as a basis for scale up to industrial scale. Results from quality control assays have proven the validity of this approach.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584609     DOI: 10.1016/0165-022x(89)90029-8

Source DB:  PubMed          Journal:  J Biochem Biophys Methods        ISSN: 0165-022X


  3 in total

1.  Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of a human monoclonal antibody specific to HIV-1-gp41.

Authors:  M Felgenhauer; J Kohl; F Rüker
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

2.  Nucleotide sequence of cDNA encoding the BYMV coat protein gene.

Authors:  K Boye; P E Jensen; B M Stummann; K W Henningsen
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

3.  Structure of a human monoclonal antibody Fab fragment against gp41 of human immunodeficiency virus type 1.

Authors:  X M He; F Rüker; E Casale; D C Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.